Abstract:Morphine tolerance remains a challenge in the management of chronic pain in the clinic. As shown in our previous study, the dopamine D2 receptor (D2DR) expressed in spinal cord neurons might be involved in morphine tolerance, but the underlying mechanisms remain to be elucidated. In the present study, selective spinal D2DR blockade attenuated morphine tolerance in mice by inhibiting phosphatidylinositol 3 kinase (PI3K)/serine–threonine kinase (Akt)-mitogen activated protein kinase (MAPK) signaling in a μ opioid receptor (MOR)-dependent manner. Levo-corydalmine (l-CDL), which exhibited micromolar affinity for D2DR in D2/CHO-K1 cell lines in this report and effectively alleviated bone cancer pain in our previous study, attenuated morphine tolerance in rats with chronic bone cancer pain at nonanalgesic doses. Furthermore, the intrathecal administration of l-CDL obviously attenuated morphine tolerance, and the effect was reversed by a D2DR agonist in mice. Spinal D2DR inhibition and l-CDL also inhibited tolerance induced by the MOR agonist DAMGO. l-CDL and a D2DR small interfering RNA (siRNA) decreased the increase in levels of phosphorylated Akt and MAPK in the spinal cord; these changes were abolished by a PI3K inhibitor. In addition, the activated Akt and MAPK proteins in mice exhibiting morphine tolerance were inhibited by a MOR antagonist. Intrathecal administration of a PI3K inhibitor also attenuated DAMGO-induced tolerance. Based on these results, l-CDL antagonized spinal D2DR to attenuate morphine tolerance by inhibiting PI3K/Akt-dependent MAPK phosphorylation through MOR. These findings provide insights into a more versatile treatment for morphine tolerance. By blocking dopamine receptors located in the spinal cord, a compound found in a traditional Chinese herbal medicine may help mitigate tolerance to morphine, a common problem among cancer patients who regularly take the opioid painkiller. A team led by Ji-Hua Liu and Bo-Yang Yu from China Pharmaceutical University in Nanjing had previously showed that inhibiting dopamine D2 receptors in spinal neurons prevented mice from developing morphine tolerance, but it wasn’t clear why. They have now demonstrated that blocking D2 receptors prevents the relay of cellular signals from morphine-binding “μ-opioid” receptors to mediators of drug tolerance. Levo-corydalmine, a compound isolated from the Asian Corydalis plant, binds and inhibits D2 receptors. When administered directly into the spinal cords of mice and rats, it blocked downstream signaling, reducing morphine tolerance.

Simultaneous inhibition of NMDA and mGlu1/5 receptors by levo-corydalmine in rat spinal cord attenuates bone cancer pain

Blockade of spinal dopamine D1/D2 receptor heteromers by levo -Corydalmine suppressed calcium signaling cascade in spinal neurons to alleviate bone cancer pain in rats

Analgesic effect of levo-corydalmine on neuropathic pain in rats and its mechanism

Levo-corydalmine Attenuates Microglia Activation and Neuropathic Pain by Suppressing ASK1-p38 MAPK/NF-κB Signaling Pathways in Rat Spinal Cord.

Levo-Corydalmine Alleviates Neuropathic Cancer Pain Induced by Tumor Compression via the CCL2/CCR2 Pathway.

Blockade of Spinal Dopamine D1/D2 Receptor Suppresses Activation of NMDA Receptor Through Gαq and Src Kinase to Attenuate Chronic Bone Cancer Pain

Levo-corydalmine alleviates vincristine-induced neuropathic pain in mice by inhibiting an NF-kappa B-dependent CXCL1/CXCR2 signaling pathway.

Intrathecal Injection of Metabotropic Glutamate Receptor Subtype 3 and 5 Agonist/Antagonist Attenuates Bone Cancer Pain by Inhibition of Spinal Astrocyte Activation in a Mouse Model

Dehydrocorydaline attenuates bone cancer pain by shifting microglial M1/M2 polarization toward the M2 phenotype

Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5

Selective Blockade of Spinal D2DR by Levo-Corydalmine Attenuates Morphine Tolerance Via Suppressing PI3K/Akt-MAPK Signaling in a MOR-dependent Manner

Stage-dependent Anti-Allodynic Effects of Intrathecal Toll-like Receptor 4 Antagonists in a Rat Model of Cancer Induced Bone Pain

Levo-corydalmine Attenuates Vincristine-Induced Neuropathic Pain in Mice by Upregulating the Nrf2/HO-1/CO Pathway to Inhibit Connexin 43 Expression

Activation of Spinal Mrgc-Gi-Nr2b-Nnos Signaling Pathway by Mas Oncogene-Related Gene C Receptor Agonist Bovine Adrenal Medulla 8-22 Attenuates Bone Cancer Pain in Mice

Suppression of KCNQ/M (kv7) Potassium Channels in the Spinal Cord Contributes to the Sensitization of Dorsal Horn WDR Neurons and Pain Hypersensitivity in a Rat Model of Bone Cancer Pain.

The Role of N‐methyl‐d‐aspartate Receptor Subunit NR2B in Spinal Cord in Cancer Pain

Relief of mechanical allodynia in rat model of bone cancer by intrathecal MCP-1 neutralizing antibody

Inhibition of Connexin 43 and Phosphorylated NR2B in Spinal Astrocytes Attenuates Bone Cancer Pain in Mice.

Curcumin analogue NL04 inhibits spinal cord central sensitization in rats with bone cancer pain by inhibiting NLRP3 inflammasome activation and reducing IL-1β production

Transient Receptor Potential Channel and Interleukin-17A Involvement in LTTL Gel Inhibition of Bone Cancer Pain in a Rat Model

Analgesic Effects of the Selective Blocking of Descending Facilitation Targeting Μ, Opioid Receptor Positive Neurons in a Rat Model of Bone Cancer Pain